Inmed Pharmaceuticals Inc. · NASDAQ:INM
Inmed Pharmaceuticals — Investor Presentation (September 2025)
25 slides from Inmed Pharmaceuticals's investor presentation, September 2025
Slide 1: Corporate Presentation
Corporate Presentation September 2025 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Highlights
Overview & Highlights InMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors • Robust R&D pipeline with 3 pharma candidates: - Alzheimer’s – multi-factorial approach, reduces neuroinflammation - Ocular – functi
Slide 4: A Clinical Stage Pharmaceutical Company
A Clinical Stage Pharmaceutical Company A GLOBAL LEADER IN THE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF RARE CANNABINOIDS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical pr
Slide 5: Drug Development Programs
Drug Development Programs
Slide 6: Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2
Pharmaceutical Pipeline: Small Molecules Targeting CB1/CB2 HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 • In vivo studies – improved neuronal function, neuroprotection, reduced neuroinflammation INM-9 01 • Improvement in cognitive function, memory, Alzheimer’s disease locomotor and anxiety-based
Slide 7: Alzheimer's Disease – A Major Medical & Societal Burden
Alzheimer’s Disease – A Major Medical & Societal Burden CURRENT TREATMENT OPTIONS DO NOT REVERSE EFFECTS What is Alzheimer’s Disease? Impact Alzheimer's is a subset of dementia that impacts • 7.2M Americans affected the part of the brain that controls thought, memory • 1 in 9 people age 65+ (11%) an
Slide 8: INM-901: A Multi-factorial Approach
INM-901: A Multi-factorial Approach A preferential signaling agonist Oral formulation that can for CB1/CB2 and impacts PPAR effectively pass the signaling pathways blood/brain barrier Increased neurite Demonstrated statistically outgrowth in in vitro significant reduction in studies, signifying INM-
Slide 9: INM-901: Potential Multiple Mechanisms of Action
INM-901: Potential Multiple Mechanisms of Action INM-901 INM-901 Cytotoxicity • Proprietary small Neuroinflammation molecule compound can cross BBB Neuroprotection • Can be formulated Neurite outgrowth orally Neuronal function • Preferential signaling Locomotion agonist for CB1/CB2 Memory • Impacts
Slide 10: Well-characterized Study Design Using 5xFAD AD Mouse Model
Well-characterized Study Design Using 5xFAD AD Mouse Model LONGER TREATMENT DURATION AND ADVANCED DISEASE STAGE + + + 9 months old male mice at study conclusion 2-month-old male mice were injected twice-weekly for 7 months After seeing positive results in short term studies we conducted this long-te
Slide 11: Results
Results - • INM-901 Demonstrates Positive Trends in Cognitive Function, Anxiety-Related Behavior and Sensory Responsiveness • Disease mice revert back to wild mice behaviour • INM-901 Demonstrates Strong Neuroinflammatory Modulation in Alzheimer’s Pathology • Significant reduction in the inflammator
Slide 12: INM-901 Next Steps
INM-901 Next Steps Research & Development • Additional mRNA, protein and histological measurements • Assess markers of neuronal differentiation & function • Evaluate stress responses & cellular growth/survival • On-going activities on CMC for drug substance and oral drug product • Further studies of
Slide 13: Impact of Dry Age-related Macular Degeneration (AMD)
Impact of Dry Age-related Macular Degeneration (AMD) LEADING CAUSE OF VISION LOSS What is AMD? AMD Opportunity AMD is an eye disease that can blur your • Affects 19.8M Americans aged 40+ central vision, eventually leading to loss • 12.6% of the U.S. population of vision. It happens when aging causes
Slide 14: AMD Occurs When the Macula is Damaged
AMD Occurs When the Macula is Damaged Back of eye Retina Retina (Macular Area) Damaged Photoreceptor macula at the cells back of the eye Retinal Pigment Epithelium Choroid Age-related Optic Macular Nerve Degeneration Dry AMD is the most common form of AMD. In the advanced stages of dry AMD, called G
Slide 15: INM-089: A Differentiated Approach to Treating Dry AMD
INM-089: A Differentiated Approach to Treating Dry AMD Ability to proactively A preferential signaling ligand protect the retinal for CB1 and CB2 ganglion cells Demonstrated promise in preserving retinal Improved the thickness of function in an INM-089 the outer nuclear layer of the retina where the
Slide 16: INM-089 Next Steps
INM-089 Next Steps Research & Development • Continuing CMC activities for drug substance and drug product • On-going studies of receptor interactions (MoA) and DMPK • Pre-IND meeting prior to GLP Studies • GLP studies to follow Business Development • Identify co-development partner and strategic inv
Slide 17: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary symptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 18: BayMedica Commercial Business
BayMedica Commercial Business
Slide 19: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONS IS TENC Y COST - EFFECTI VEN ESS High quality, bioidentical rare cannabinoids with exceptional Multipl
Slide 20: BayMedica Financial Performance
BayMedica Financial Performance Calendar Year Revenue Growth US$ (Fiscal year ends June 30) (000’s) 1,400 • Trailing 12-month revenue is $4.8M 1,200 • Volumes of Kgs sold have more than doubled 1,000 over the last 18 months 800 • Currently operating as a cash flow positive 600 business 400 200 • For
Slide 21: Corporate
Corporate
Slide 22: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT Eric A. Adams, MIBS Neeta Jagpal, CPA Michael Woudenberg, PEng Colin Clancy Shane Johnson, MD Chief Executive Officer Chief Financial Officer Chief Operating Officer VP, IR & Corp Comms SVP & GM, BayMedica 30+ years of
Slide 23: Financial Snapshot
Financial Snapshot Cash and Short-term Investments $9.2M(1) Shares I/O 4.2 M(2) Options 62 K Warrants and Preferred Investment Options 2.4 M Fully Diluted Shares 6.7 M Close $2.40 52-week High $15.60 52-week Low $1.72 Average Daily Volume (Trailing 50 Days) 2.3 M Market Cap $10 M(3) (1) Includes cas
Slide 24: 2025/2026 – Key Value Drivers
2025 /2026 – Key Value Drivers • Advance INM-901 in ALZ towards IND filing / subsequent human clinical trials • Develop INM-089 in Dry AMD towards IND filing / subsequent human clinical trials • Target additional proprietary drug candidates for pharma R&D pipeline • Identify and execute on strategic
Slide 25: Thank you!
Thank you! Forward Inquiries to, Colin Clancy Vice President, Investor Relations & Corporate Communications ir@inmedpharma.com +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (September 2025) on 6ix